Molecular Insight Pharmaceuticals is specializing in the emerging field of

Tag : Pharmaceuticals
The Company's Board said: "The Board determined that newleadership at the Chair and CEO level was necessary for the Companyto execute on its strategic plan. We believe that the Company iswell-positioned with the right infrastructure and strong productcandidates in the FDA approval process to exploit its marketopportunities. A strong CEO, working closely with a Board that wasrecently expanded with four industry leaders in healthcare, willbest position the Company to achieve its objectives. We thank Davidfor his contributions and wish him all the best in his futureendeavors."
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is abiopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification andtargeting of disease at the molecular level to improve healthcarefor patients with life-threatening diseases. The Company is focusedon discovering, developing and commercializing innovative molecularimaging radiopharmaceuticals and targeted molecularradiotherapeutics with initial applications in the areas ofcardiology and oncology. Molecular Insight's lead molecular imagingradiopharmaceutical product candidate, Zemiva, is being developedfor the diagnosis of cardiac ischemia, or insufficient blood flowto the heart. The Company's imaging candidate Trofex is indevelopment for the detection of metastatic prostate cancer.Molecular Insight's lead molecular radiotherapeutic productcandidates, Azedra and Onalta, are being developed for detectionand treatment of cancer. In addition, the Company has a growingpipeline of product candidates resulting from application of itsproprietary platform technologies to new and existing compounds.Molecular Insight Pharmaceuticals is based in Cambridge,Massachusetts and its website address is: www.molecularinsight.com.
Forward-Looking Statements
Statements in this release that are not strictly historical innature constitute "forward-looking statements." Suchstatements include, but are not limited to, statements about thedevelopment of Azedra(TM), Onalta(TM), Zemiva(TM), Trofex(TM) andour other product candidates. Such forward-looking statementsinvolve known and unknown risks, uncertainties, and other factorsthat may cause the actual results of Molecular Insight to bematerially different from historical results or from any resultsexpressed or implied by such forward-looking statements. Thesefactors include, but are not limited to, risks and uncertaintiesrelated to the progress, timing, cost, and results of clinicaltrials and product development programs; difficulties or delays inobtaining regulatory approval for product candidates; competitionfrom other pharmaceutical or biotechnology companies; and theadditional risks discussed in filings with the Securities andExchange Commission. All forward-looking statements are qualifiedin their entirety by this cautionary statement, and MolecularInsight undertakes no obligation to revise or update this newsrelease to reflect events or circumstances after the date hereof.
Contact
Molecular Insight Pharmaceuticals, Inc.
Corporate Communications
Priscilla Harlan, 617-492-5554
or
Investor Relations
Deborah S. Lorenz, 617-871-6667 Printer Friendly Version Forward to a Friend